Skip to main content
Signal8

Thye Dirk

SEC insider (Form 3/4/5 filer). CIK 0001638945. CEO and CMO at Quince Therapeutics, Inc. (QNCX). 7 reported Form 4/5 transactions since Sep 2024; latest on Jan 23, 2026. Located in SOUTH SAN FRANCISCO, CA.

Companies Thye Dirk has filed insider reports for

  • Quince Therapeutics, Inc. (QNCX): Director, Officer, CEO and CMO
Thye Dirk profile photo

Thye Dirk

CIK: 0001638945

Transaction Breakdown

Open Market Buys (P)2 (28.6%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (42.9%)

Compensation grants

Other (G, F, J, C, D, …)2 (28.6%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

Quince Therapeutics, Inc. logo
QNCX

Quince Therapeutics, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (7 total)

  • Quince Therapeutics, Inc. logo
    QNCX

    Quince Therapeutics, Inc.

    Jan 23, 2026
    Award

    Employee Stock Option (Right to Buy)

    Direct
    1M shares-
  • Quince Therapeutics, Inc. logo
    QNCX

    Quince Therapeutics, Inc.

    Dec 10, 2025
    Gift
    Indirect
    739.9K shares-
  • Quince Therapeutics, Inc. logo
    QNCX

    Quince Therapeutics, Inc.

    Dec 10, 2025
    Gift
    Direct
    739.9K shares-
  • Quince Therapeutics, Inc. logo
    QNCX

    Quince Therapeutics, Inc.

    Jun 18, 2025
    Award
    Direct
    150.9K shares at avg. $1.20$181K
  • Quince Therapeutics, Inc. logo
    QNCX

    Quince Therapeutics, Inc.

    Jan 28, 2025
    Award

    Employee Stock Option (right to buy)

    Direct
    1.2M shares-
  • Quince Therapeutics, Inc. logo
    QNCX

    Quince Therapeutics, Inc.

    Aug 30, 2024
    Purchase
    Direct
    77K shares at avg. $0.70$54K
  • Quince Therapeutics, Inc. logo
    QNCX

    Quince Therapeutics, Inc.

    Aug 29, 2024
    Purchase
    Direct
    77.5K shares at avg. $0.69$53K

1-7 of 7